Skip to content

IDESPHARMA

Active
Private limited companyfounded 2021active for 5 yearsDageraadstraat(Kok) 11, 8670 Koksijde, BelgiumKBO/BCE: BE 0764.318.824
Summary

IDESPHARMA has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €353,392 and a net result of -€6,436. Equity is growing by about 27% per year across the filed financial years. Its solvency ranks better than 39% of 12,737 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.5% (low).

Overview

Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
≈ €890,000turnover 2025, estimated
Staff
2 FTE
Equity
€353,392
Loss
-€6,436
Turnover estimated from the gross margin
Financial health
81 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.5%
Structure
2025 accounts 147 days early2 of 3 deeds summarised
Why 81raises riskFounded in 2021Loss of €6,436 (financial year 2025)lowers riskFigures for financial year 2025 (filed 06-12-2025)Size: 2 FTE, total assets €1.3mShow the evidence

Checked score

Score 2025
81 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 47% of its sector peers (NACE 47, micro)
Financial strength · tick = 2024
Average
Solvency 51=
equity 26.4% of total assets
Liquidity 56+4
short-term debt 6.6% · cash 4.5%
Profitability 68-10
return on assets -0.5%
Bankruptcy probability, 12 months
0.5% Low
0%0.5%1.5%4%10%≥ 25%

About 5 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,268 companies, NACE 47, micro)
Last 24 months 11-2024: 0.8% 12-2024: 0.8%● unchanged vs 11-2024 01-2025: 1.3%▲ +0.5 percentage points vs 12-2024highest value 02-2025: 1.2%▼ -0.1 percentage points vs 01-2025 03-2025: 1.2%● unchanged vs 02-2025 04-2025: 1.2%● unchanged vs 03-2025 05-2025: 1.2%● unchanged vs 04-2025 06-2025: 0.6%▼ -0.6 percentage points vs 05-2025 07-2025: 0.6%● unchanged vs 06-2025 08-2025: 0.6%● unchanged vs 07-2025 09-2025: 0.6%● unchanged vs 08-2025 10-2025: 0.6%● unchanged vs 09-2025 11-2025: 0.6%● unchanged vs 10-2025 12-2025: 0.6%● unchanged vs 11-2025 01-2026: 0.6%● unchanged vs 12-2025 02-2026: 0.6%● unchanged vs 01-2026 03-2026: 0.6%● unchanged vs 02-2026 04-2026: 0.6%● unchanged vs 03-2026 05-2026: 0.6%● unchanged vs 04-2026 06-2026: 0.6%● unchanged vs 05-2026 07-2026: 0.6%● unchanged vs 06-2026 08-2026: 0.6%● unchanged vs 07-2026 09-2026: 0.6%● unchanged vs 08-2026 10-2026: 0.5%▼ -0.1 percentage points vs 09-2026lowest value
Credit of up to €25,000 on 30-day terms is acceptable
Liquidity ample (current ratio 3.92, compared with 2.8 in 2024, above the usual 1.5; short-term debt: 6.6% and cash: 4.5% of total assets), but 73.6% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro): better than 42% on solvency, 61% on liquidity, 48% on profitability and 35% on growth.

The bankruptcy probability was computed on 30-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises riskneutral
raises risk · Founded in 2021
Companies of this age fail more often than older ones; how much that weighs depends on the rest of its profile.
KBO
lowers risk · Figures for financial year 2025 (filed 06-12-2025)
NBB · annual accounts
lowers risk · Size: 2 FTE, total assets €1.3m
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
raises risk · Loss of €6,436 (financial year 2025)
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 04-12-2025, 147 days ahead of the deadline.
NBB · 4 filings
Deviation from the deadline
2025
147 days early
2024
138 days early
2023
113 days early
2022
41 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 4 accounts on average 110 days before the deadline; the sector median (NACE 47) for financial year 2024 is on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-09-2026 is due by 30-04-2027. Nothing is late today. The company usually files around 26 December (3 of the last 4 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
30-09-2026 year end31-10-2026 today30-04-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · abbreviated…
  2. Weakest financial yearnet -€6,436
  3. Annual accounts filedfinancial year 2024 · abbreviated…

Financials · financial year 2025, abbreviated format

Turnover
≈ €890,000
Estimated: probably between €610,000 and €1.7m
Total assets
€1.3m▼ 1.8%
2024 · €1.4m
Net result
-€6,436
2024 · €97,266
Working capital
€259,776▼ 0.6%
2024 · €261,394
Trend over the years

2022 to 2025, 4 financial years

The operating result turns negative in 2025: a loss of €3,651 after €149,395 in 2024, the lowest result in the available series.

What the company sold each financial year and what was left of it. A loss stands below the zero line.

Operating result-€0.004m 2025 Net result-€0.006m 2025

Use the arrow keys on the chart for the figures per year.

Sector: the middle half of NACE 47, Retail trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).

Every figure with its change against the financial year before
favourable unfavourable
Line2022202320242025
Operating result€0.2m-€0.2m▼ 16.9%€0.1m▼ 9.6%-€0.004m
Net result€0.1mabove the sector's middle half-€0.1mwithin the sector's middle half▼ 19.1%€0.1mwithin the sector's middle half▼ 15.5%-€0.006mbelow the sector's middle half
Equity€0.1mwithin the sector's middle half-€0.3mwithin the sector's middle half▲ 78.1%€0.4mwithin the sector's middle half▲ 37.0%€0.4mwithin the sector's middle half▼ 1.8%
Total assets€0.4mbelow the sector's middle half-€0.5mbelow the sector's middle half▲ 22.1%€1.4mwithin the sector's middle half▲ 184%€1.3mwithin the sector's middle half▼ 1.8%
Debt€0.2m-€0.2m▼ 11.5%€1.0m▲ 361%€1.0m▼ 1.8%
Working capital€0.2mwithin the sector's middle half-€0.2mwithin the sector's middle half▲ 11.9%€0.3mwithin the sector's middle half▲ 14.1%€0.3mwithin the sector's middle half▼ 0.6%
Solvency37.5%within the sector's middle half-54.7%within the sector's middle half▲ 17.2pp26.4%within the sector's middle half▼ 28.3pp26.4%within the sector's middle half=
Current ratio2.93above the sector's middle half-3.36above the sector's middle half▲ 0.432.80within the sector's middle half▼ 0.563.92above the sector's middle half▲ 1.12
Return on assets (ROA)36.2%above the sector's middle half-24.0%above the sector's middle half▼ 12.2pp7.1%within the sector's middle half▼ 16.8pp-0.5%below the sector's middle half▼ 7.6pp
Staff (FTE)0.4below the sector's middle half-1below the sector's middle half▲ 150%1below the sector's middle half=2within the sector's middle half▲ 100%
above within below the middle half of NACE 47, Retail trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Turnover and EBIT margin not published: the abbreviated format does not require them. The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €1.3m
Fixed assets €991,306 ▲ 3.5%
Current assets €348,666 ▼ 14.3%
Equity and liabilities €1.3m
Equity €353,392 ▼ 1.8%
Debt €986,579 ▼ 1.8%
Debt's share of the balance-sheet total stays at 73.6%.
Key figures and ratios
2025 value · change against 2024
EBITDA
€28,060▼
2024 · €177,640
Cash flow
€25,274▼
2024 · €125,511
Quick ratio
1.56▲
2024 · 1.18
Debt to equity
2.79=
2024 · 2.79
ROE
-1.8%▼
2024 · 27.0%
Interest coverage
14.62▼
2024 · 51.88
Debt ≤ 1 year
€88,890▼
2024 · €145,416
Debt > 1 year
€897,690▲
2024 · €859,353
Income taxes
€866▼
2024 · €48,705
Staff costs
€162,690▲
2024 · €66,540
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 46 lines
Balance sheet Code20242025
Assets
Total assets20/58€1.4m€1.3m▼
Fixed assets21/28€1.0m€1.0m▲
Tangible fixed assets22/27€0.1m€0.1m▼
Plant, machinery and equipment23€0.04m€0.03m▼
Furniture and vehicles24€0.1m€0.07m▼
Financial fixed assets28€0.8m€0.9m▲
Current assets29/58€0.4m€0.3m▼
Stocks and contracts in progress3€0.2m€0.2m▼
Stocks30/36€0.2m€0.2m▼
Amounts receivable within one year40/41€0.1m€0.08m▼
Trade receivables40€0.09m€0.05m▼
Other amounts receivable41€0.06m€0.03m▼
Cash at bank and in hand54/58€0.03m€0.06m▲
Deferred charges and accrued income490/1€157€0.002m▲
Equity and liabilities
Total equity and liabilities10/49€1.4m€1.3m▼
Equity10/15€0.4m€0.4m▼
Contributions10/11€0.005m€0.005m=
Reserves13€0.4m€0.4m=
Distributable reserves133€0.4m€0.4m=
Profit (loss) carried forward14--€0.006m
Amounts payable17/49€1.0m€1.0m▼
Amounts payable after more than one year17€0.9m€0.9m▲
Financial debts170/4€0.02m-
Other amounts payable178/9€0.8m€0.9m▲
Amounts payable within one year42/48€0.1m€0.09m▼
Current portion of amounts payable after more than one year42€0.02m€0.02m▼
Trade debts44€0.1m€0.05m▼
Suppliers440/4€0.1m€0.05m▼
Taxes, remuneration and social security45€0.02m€0.02m▲
Taxes450/3€0.01m€0.004m▼
Remuneration and social security454/9€0.009m€0.02m▲
Income statement Code20242025
Remuneration, social security and pensions62€0.07m€0.2m▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€0.03m€0.03m▲
Other operating charges640/8€0.001m€0.001m▼
Gross operating margin9900€0.2m€0.2m▼
Operating profit (loss)9901€0.1m-€0.004m▼
Financial charges65/66B€0.003m€0.002m▼
Recurring financial charges65€0.003m€0.002m▼
Profit (loss) for the period before taxes9903€0.1m-€0.006m▼
Income taxes67/77€0.05m€0.001m▼
Profit (loss) for the period9904€0.1m-€0.006m▼
Profit (loss) for the period to be appropriated9905€0.1m-€0.006m▼
Appropriation of the result
Profit (loss) to be appropriated9906€0.1m-€0.006m▼
Transfer to equity691/2€0.1m-
To other reserves6921€0.1m-
Social balance sheet
Average headcount (FTE)90871.02.0▲

The notes to these accounts (7 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line2022202320242025Change
Remuneration, social security and pensions62€25,656€68,630€66,540€162,690▲ 144%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€9,848€15,748€28,245€31,711▲ 12.3%
Other operating charges640/8€62€423€1,021€700▼ 31.4%
Gross operating margin9900€234,312€249,994€245,201€191,450▼ 21.9%
Operating profit (loss)9901€198,746€165,193€149,395-€3,651-
Financial charges65/66B€807€1,920€3,424€1,919▼ 43.9%
Recurring financial charges65€807€1,920€3,424€1,919▼ 43.9%
Profit (loss) for the period before taxes9903€197,939€163,273€145,971-€5,570-
Income taxes67/77€55,533€48,116€48,705€866▼ 98.2%
Profit (loss) for the period9904€142,406€115,157€97,266-€6,436-
Profit (loss) for the period to be appropriated9905€142,406€115,157€97,266-€6,436-
Line2022202320242025Change
Assets
Total assets20/58€0.4m€0.5m€1.4m€1.3m▼ 1.8%
Fixed assets21/28€0.08m€0.2m€1.0m€1.0m▲ 3.5%
Tangible fixed assets22/27€0.07m€0.1m€0.1m€0.1m▼ 23.4%
Plant, machinery and equipment23€0.04m€0.04m€0.04m€0.03m▼ 13.8%
Furniture and vehicles24€0.02m€0.09m€0.1m€0.07m▼ 27.2%
Financial fixed assets28€0.02m€0.02m€0.8m€0.9m▲ 7.9%
Current assets29/58€0.3m€0.3m€0.4m€0.3m▼ 14.3%
Stocks and contracts in progress3€0.1m€0.2m€0.2m€0.2m▼ 10.4%
Stocks30/36€0.1m€0.2m€0.2m€0.2m▼ 10.4%
Amounts receivable within one year40/41€0.04m€0.05m€0.1m€0.08m▼ 47.9%
Trade receivables40€0.03m€0.05m€0.09m€0.05m▼ 47.1%
Other amounts receivable41€0.008m-€0.06m€0.03m▼ 49.0%
Cash at bank and in hand54/58€0.1m€0.08m€0.03m€0.06m▲ 139%
Deferred charges and accrued income490/1--€157€0.002m▲ 985%
Equity and liabilities
Total equity and liabilities10/49€0.4m€0.5m€1.4m€1.3m▼ 1.8%
Equity10/15€0.1m€0.3m€0.4m€0.4m▼ 1.8%
Contributions10/11€0.005m€0.005m€0.005m€0.005m=
Reserves13€0.1m€0.3m€0.4m€0.4m=
Distributable reserves133€0.1m€0.3m€0.4m€0.4m=
Profit (loss) carried forward14----€0.006m-
Amounts payable17/49€0.2m€0.2m€1.0m€1.0m▼ 1.8%
Amounts payable after more than one year17€0.1m€0.1m€0.9m€0.9m▲ 4.5%
Financial debts170/4-€0.04m€0.02m--
Other amounts payable178/9€0.1m€0.08m€0.8m€0.9m▲ 6.6%
Amounts payable within one year42/48€0.1m€0.1m€0.1m€0.09m▼ 38.9%
Current portion of amounts payable after more than one year42-€0.02m€0.02m€0.02m▼ 22.2%
Trade debts44€0.04m€0.03m€0.1m€0.05m▼ 53.5%
Suppliers440/4€0.04m€0.03m€0.1m€0.05m▼ 53.5%
Taxes, remuneration and social security45€0.07m€0.04m€0.02m€0.02m▲ 17.4%
Taxes450/3€0.06m€0.03m€0.01m€0.004m▼ 65.4%
Remuneration and social security454/9€0.008m€0.01m€0.009m€0.02m▲ 114%
Line2022202320242025Change
Profit (loss) for the period9904€142,406€115,157€97,266-€6,436-
+ Depreciation and write-downs630€9,848€15,748€28,245€31,711▲ 12.3%
Operating cash flow (approximation)€152,253€130,905€125,511€25,274▼ 79.9%
Investment in fixed assets (approximation)--€87,348-€831,906-€65,229▲ 92.2%
Change in cash--€49,773-€59,287€35,041-

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Filings with the National Bank (4)
Financial year Type Filed Reference
30-09-2025 abbreviated format 04-12-2025 2025-00576804
30-09-2024 abbreviated format 13-12-2024 2024-00615787
30-09-2023 abbreviated format 08-01-2024 2024-00544912
30-09-2022 abbreviated format 20-03-2023 2023-00042641

Similar companies · same sector, comparable size

Of the 5,204 active companies whose main activity is retail sale of pharmaceutical products (NACE 47730), figures are known for 3,907. 3,477 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector

Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.

Directors

Directors
1 director, last change in 2024
Sam Laeremans
Director · since 01-10-2024
Current
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ. See the directors and other office holders in the KBO →
Not every act has been read: a resignation may still be missing
1 of this company's 3 Belgian Official Gazette deeds has not been read yet. Appointments and resignations recorded in them are not yet in the list of directors: someone who resigned there may still be listed as sitting. The acts are in the Timeline.

Mandate history

1 person since 2024, 1 in office
Show
  • Board
Mandates per person, with start and end dates
Name Functions and periods
Sam Laeremans
  • Director, from 01-10-2024 to date
See the board, name and registered office on a given date →

Owners and capital

Owners

No owners or capital events in the accounts and acts we read.

Group and network

Connections & network

1 current director
Depth

The board mandates are listed below; here you explore them as a network.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.

Board mandates elsewhere

1 board mandate
Board mandates of this companythis company sits on their board1

History

IDESPHARMA was incorporated on 24 February 2021 as a private limited company.1 The registered office was moved to Koksijde in 2023.2 Total assets rose from €393,510 in 2022 to €1.3m in 2025 and headcount from 0.4 to 2 full-time equivalents.3

  1. 1KBO register
  2. 2Belgian Official Gazette, 24-05-2023
  3. 3National Bank, annual accounts 2022 and 2025

Acts, filings and financial milestones

Next filing, financial year 2026, expected by 30-04-2027
2025
04-12
NBB filing Annual accounts filed
financial year 2025 · abbreviated format
30-09
Financial Weakest financial yearnet -€6,436
Net result drops to -€6,436, the lowest in the series.
2024
13-12
NBB filing Annual accounts filed
financial year 2024 · abbreviated format
24-10
Gazette deed Appointment: Sam Laeremans (director)
2 facts ▸
  • General meeting, 01-10-2024
  • Director appointment, Sam Laeremans (director)
08-01
NBB filing Annual accounts filed
financial year 2023 · abbreviated format
2023
30-09
Financial Equity above €200,000equity €262,562 ▲78.1%
A profit in every financial year since 2022 builds equity to €262,562.
24-05
Gazette deed Registered office
Registered-office move2 facts ▸
  • Board meeting, 21-04-2023
  • Registered-office move, Dageraadstraat 11,8670 Koksijde
20-03
NBB filing Annual accounts filed
financial year 2022 · abbreviated format
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
2 of 3 deeds read
About the unread acts

Of the 3 Belgian Official Gazette deeds we know for this company, 2 have been read. The other one has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Register details

Identification
Legal formPrivate limited company
Founded24-02-2021
Financial year end30-09
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
47279Other retail sale of food
47750Retail sale of cosmetics and toilet articles
E-invoicing
Reachable via Peppol
Peppol ID 0208:0764318824
Also 9925:BE0764318824
Registered 12-02-2025

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 30 October 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.

Recognitions · licences · registrations

Food safety, FASFC

1 site
Koksijdeunit no. 2.314.089.903
1 permission
Apotheek (LM>3 maand) · since 01-04-2021

Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.

Sites & property

Location & real-estate footprint
Registered office, Koksijde · 1 establishment unit since 2021
registered office establishment The establishment unit on the map
Ground area
2,068 m²
Building footprint
266 m²
Building volume
1,507 m³
2 parcels, Flanders · tallest building 13.0 m. Linked by address, not a title deed.
1 establishment unit
IDESPHARMA
Strandlaan(Kok) 282, 8670 KoksijdeRetail sale of pharmaceutical products
since 2021unit no. 2.314.089.903
2 parcels
Flanders 2 (100%)
Cadastral parcel Region Area Buildings Height / floors
38343A0898/00C009 Flanders 1,627 m² 1 · 176 m² 6.6 m · 1
38014D0399/00C000 Flanders 441 m² 1 · 90 m² 13.0 m · 3
How the parcels are linked
Good to know
Both parcels match the address exactly.